Correction to: Weight Reduction and Pioglitazone are Cost-Effective for the Treatment of Non-alcoholic Fatty Liver Disease in Thailand (PharmacoEconomics, (2019), 37, 2, (267-278), 10.1007/s40273-018-0736-0)

Chongmelaxme, B., Phisalprapa, P., Manthaisong, R., Dilokthornsakul, P., & Chaiyakunapruk, N. (2019, February 13). Correction to: Weight Reduction and Pioglitazone are Cost-Effective for the Treatment of Non-alcoholic Fatty Liver Disease in Thailand (PharmacoEconomics, (2019), 37, 2, (267-278), 10.1007/s40273-018-0736-0). PharmacoEconomics. Springer International Publishing. https://doi.org/10.1007/s40273-018-0754-y